Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae [Corrigendum]

Chen D, Lan H, Yang W, et al. Infect Drug Resist. 2026;19:1—13. https://doi.org/10.2147/IDR.S583973

There is an unintentional textual error in Figure 1 on page 4 of the published paper, the text “(n=4: CRAB, n=3; CRKP, n=1)” should read “(n=20: CRAB, n=15; CRKP, n=5)”.

The authors apologize for the error and advise that it was purely a labelling oversight and does not alter the statistical analysis, results, or the scientific conclusions of the paper. The correct Figure 1 is shown below.

Figure 1 Experimental Workflow.

Read the original article

© 2026 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.